VKTX$32.87
Chart
Performance
Key Stats
AI VKTX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldThe company shows thematic promise in the biopharmaceutical sector with a specialized clinical-stage pipeline, but fundamental challenges and mixed technical signals suggest cautious investment. Suitable for risk-tolerant investors focusing on long-term potential.
Thematic
Viking Therapeutics operates in the innovative biopharmaceutical space targeting metabolic and endocrine disorders with advanced-stage clinical trials in multiple drug candidates.
Fundamental
The company faces ongoing financial challenges with negative earnings, negative free cash flow, and significant debt levels, indicating high risk. Valuation remains unattractive based on negative earnings multiples.
Technical
Technical indicators show mixed signals with short-term oscillators suggesting a potential pullback, while many moving averages indicate underlying strength. Volume confirms moderate investor interest.
| Factor | Score |
|---|---|
| Biopharmaceutical Innovation | 85 |
| Market Opportunity | 75 |
| Company Maturity | 70 |
| Regulatory Environment | 60 |
| ESG & Sustainability | 70 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 25 |
| Growth | 40 |
| Balance Sheet Health | 70 |
| Cash Flow | 25 |
| Factor | Score |
|---|---|
| Trend Analysis | 70 |
| Momentum | 55 |
| Volume Confirmation | 60 |
| Support & Resistance | 60 |
AI Investing Checklist
Powered by LiveAIBullish Points (5)
Positive Earnings Surprises
Recent quarterly EPS reports showed positive surprises in 2024 Q2 and Q3, with reported EPS beating estimates by up to 25.93%, indicating earnings performance exceeding expectations.
Strong Equity Position
The company has a solid total equity of approximately $880 million against liabilities below $28 million, indicating a strong balance sheet and good financial stability.
Bearish Points (7)
Negative Earnings Trend and Losses
The company reports negative EPS consistently with trailing twelve months EPS at -1.16 and net losses exceeding $100 million, reflecting ongoing unprofitability.
Negative and Declining P/E Ratios
The P/E ratios remain negative and have deteriorated sharply in recent quarters (e.g., -285.1 in 2024 Q3) indicating earnings are negative with no clear path to profitability in the near term.
Calendar
July 2025
24
Next Earnings Date
H: $-0.37
A: $-0.44
L: $-0.55
Profile
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Seasonals
Price Target
90.26 USD
The 39 analysts offering 1 year price forecasts for VKTX have a max estimate of 125.00 and a min estimate of 30.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Shares focus on biotech and innovative therapies in genetic and rare diseases
Weight: 93
Major biotech player with overlapping therapeutic areas and strong R&D pipeline
Weight: 90
Biotech company specializing in oncology, similar innovative drug development focus
Weight: 88
Specializes in rare diseases and biologics, similar to VKTX’s rare disease focus